In December 2018, Robin Emerson persuaded a private neurologist in London to help his daughter Jorja. She became one of the first children in the UK, and the first after the November 2018 law change, to be prescribed medical cannabis. The date matters, but the story is not simply about a date. It is about the distance between a decision in law and a family being able to rely on access in everyday life.
The background
Jorja was born with a rare chromosome disorder. At around 10 months old it triggered severe epilepsy, and every seizure was potentially life threatening. In 2017, doctors in Northern Ireland told the family to prepare to say goodbye. Robin refused to accept that nothing could be done. He researched evidence worldwide and spoke to clinicians and families in the US, Canada and Australia.
He campaigned for the law to change. On 1 November 2018, cannabis based products for medicinal use became legal to prescribe in the UK. In December 2018, after Robin persuaded a private neurologist in London to help, Jorja became one of the first children in the UK, and the first after the November 2018 law change, to be prescribed medical cannabis. The family flew to London for repeat prescriptions.
Robin gave written evidence to the House of Commons Health and Social Care Committee on access to medical cannabis. That evidence included the supply interruptions families faced. In January 2020, he joined Cannaray as Patient Advocate Director, and Jorja's prescription was fulfilled through that partnership. These events belong to the history of the family's access, not to a recommendation for another patient.
In 2021, the specialist prescribing for Jorja retired, highlighting how fragile access was for children. Robin continued to campaign, including at Parliament in 2022 alongside a public petition for NHS access. Retirement is an ordinary event in a professional life. In this personal story, it also brought the question of continuity into focus. A useful policy discussion asks how responsibility can continue when the people involved change.
In 2023, Robin opened the clinic then known as the Jorja Emerson Centre, now Jorja Medical Cannabis, near Paddington, London. He gave a keynote at Cannabis Europa London 2023 on his journey from activist to business owner. Business of Cannabis reported Jorja as seizure free and thriving. That is a report about Jorja's personal experience. It cannot establish what any medicine will do for another person, and it should not be read as a general treatment claim.
Today, Robin leads Jorja Revive. His work on government relations seeks to professionalise the UK medical cannabis framework and build a coalition of responsible operators, with an international outlook. This places access and accountability within the same conversation. The purpose of an editorial account is to explain that direction, not to promote a clinical service or encourage a reader to seek a prescription.
What the milestone leaves us with
The December prescription belongs within this longer chronology. A family reached a significant point after the law changed, yet questions about continuity did not disappear. For policymakers, the distinction is worth keeping in view. Permission to prescribe and a reliable framework are not interchangeable ideas. For readers encountering Jorja's story for the first time, the same care applies to its reported outcome. Her experience is personal, and the decisions of any other patient belong with a qualified clinician. Remembering that boundary allows the story to remain both human and responsible.
